Traynor Capital Management, Inc. Crispr Therapeutics Ag Transaction History

Traynor Capital Management, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 01, 2022	SELL	$70.09 - $111.29 $1.84 Million - $2.92 Million	-26,195 Closed	0 $0
Q3 2021 Oct 25, 2021	BUY	$110.2 - $156.64 $1.24 Million - $1.76 Million	11,248 Added 75.25%	26,195 $2.93 Million
Q2 2021 Jul 21, 2021	BUY	$100.84 - $161.89 $1.27 Million - $2.03 Million	12,561 Added 526.45%	14,947 $2.33 Million
Q1 2021 May 04, 2021	BUY	$110.72 - $210.04 $3,432 - $6,511	31 Added 1.32%	2,386 $290,000
Q4 2020 Jan 14, 2021	BUY	$79.67 - $173.23 $4,780 - $10,393	60 Added 2.61%	2,355 $360,000
Q3 2020 Oct 26, 2020	BUY	$78.5 - $100.64 $180,157 - $230,968	2,295 New	2,295 $212,000
Q4 2019 Jan 24, 2020	SELL	$36.68 - $73.13 $251,074 - $500,574	-6,845 Closed	0 $0
Q3 2019 Nov 01, 2019	BUY	$40.99 - $52.56 $15,371 - $19,710	375 Added 5.8%	6,845 $280,000
Q2 2019 Jul 26, 2019	BUY	$35.45 - $48.2 $229,361 - $311,854	6,470 New	6,470 $308,000

493

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.97B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Traynor Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Traynor Capital Management, Inc. with notifications on news.